SCHEMBL29506544

SCHEMBL29506544

CN1CCN(c2ccc(Nc3ncc4c(n3)N3CCN=C3N(c3cc(Cl)ccc3Cl)C4=O)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 6/20 0.51
▸ PAK4 O96013 1/20 0.49
▸ PAK1 Q13153 1/20 0.49
▸ PKN1 Q16512 1/20 0.49
▸ PLK1 P53350 1/20 0.49
▸ SRC P12931 4/20 0.49
▸ JAK2 O60674 2/20 0.49
▸ MAPK7 Q13164 2/20 0.48
▸ LRRK2 Q5S007 2/20 0.48
▸ LCK P06239 2/20 0.48
▸ HCK P08631 1/20 0.48
▸ FGFR1 P11362 1/20 0.47
▸ FGFR2 P21802 1/20 0.47
▸ FGFR4 P22455 1/20 0.47
▸ FGFR3 P22607 1/20 0.47
▸ ALK Q9UM73 1/20 0.47
▸ BRD4 O60885 3/20 0.46
▸ TNK2 Q07912 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373383 1.00 WEE1 (0.51) WEE1PAK4PAK1PKN1PLK1
SCHEMBL29506555 0.94 WEE1 (0.54) WEE1PAK4PAK1PKN1PLK1
SCHEMBL21373340 0.94 WEE1 (0.54) WEE1PAK4PAK1PKN1PLK1
SCHEMBL29506508 0.90 WEE1 (0.55) WEE1SRCJAK2LRRK2FGFR1
SCHEMBL20180608 0.90 WEE1 (0.55) WEE1SRCJAK2LRRK2FGFR1
SCHEMBL21373461 0.90 WEE1 (0.53) WEE1PAK4PAK1PKN1PLK1
SCHEMBL21373308 0.89 WEE1 (0.53) WEE1PAK4PAK1PKN1PLK1
SCHEMBL21373353 0.87 WEE1 (0.65) WEE1SRCJAK2MAPK7LRRK2
SCHEMBL29506482 0.87 WEE1 (0.65) WEE1SRCJAK2MAPK7LRRK2
SCHEMBL21373290 0.87 WEE1 (0.55) WEE1SRCJAK2LCKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 — — EP claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback